A treatment for the fatal lung disease idiopathic pulmonary fibrosis (IPF) has been identified by Mayo Clinic researchers. They found that the anti-cancer drug imatinib mesylate - commercially known as Gleevec and produced by Novartis Pharmaceuticals - could target a gene critical to controlling the disease process. Now the treatment is undergoing clinical trials at Mayo Clinic.

The Mayo Clinic researchers describe their investigation in laboratory mice in the current edition of the Journal of Clinical Investigation. The gene they identified is known as c-Abl, and it initiates the destructive, abnormal growth of lung tissue. Moreover, the drug Gleevec inhibits c-Abl. Because Gleevec was already approved by the US FDA for use in certain cancers, the researchers were able to speed the Gleevec treatment into human trials.

"I treat patients with this disease, and to have to tell someone they have this lethal disease and that there's no treatment for it is just devastating for them," says first author Craig Daniels. "Even though these are animal studies and the results still need to be investigated in humans, we certainly know more now than we did a few years ago, or even a year ago, and this tells me we eventually will find a standard treatment for IPF. That's the best part. That will be one of the happiest days of my life when that's true," he added.

"The nice thing about this study is that it shows that since TGF Beta and PDGF are two of the most pro-fibrotic growth factors known - and Gleevec inhibits the action of both - one treatment works on multiple targets," Edward Leof, senior author and principal investigator of the preclinical study says adding, "And because TGF Beta and PDGF are such strong and widespread pro-fibrotic growth factors, our findings suggest that many fibrotic diseases will likely be impacted by this, not just pulmonary fibrosis - kidney fibrosis, for example, and fibrotic cancer tumours."

Andrew Limper, a Mayo Clinic pulmonologist and principal investigator of the clinical trial said, "It is truly exciting to see how rapidly these cellular studies were first shown effective in mice, and we now are testing the agent in patients with lung fibrosis."